We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 895

The coenzyme Q10 “saga”
  • HFG Law & Intellectual Property
  • China
  • January 11 2016

In the fast-evolving world of food and health-food regulation, two recent court decisions deserve our attention as they rule in opposite direction a


Trademark Invalidation through Administrative Procedure
  • CCPIT Patent & Trademark Law Office
  • China
  • January 6 2016

Siemens, a German multinational conglomerate company, is one of the world's most prominent makers of medical diagnostics equipment, including CT, MR


Chinese pharma company fined for refusal to supply downstream competitors
  • Hogan Lovells
  • China
  • December 23 2015

On 22 December 2015, the State Administration for Industry and Commerce ("SAIC") published the decision of its local branch in Chongqing ("Chongqing


Insight into recent PRB decisions on pharmaceutical biotech inventions
  • Peksung Intellectual Property Ltd
  • China
  • December 11 2015

The Patent Reexamination Board (hereinafter referred to as the PRB) is an organization under the SIPO (State Intellectual Property Office) of China


News and cases from China: August - September 2015
  • Rouse
  • China
  • October 29 2015

Recently, the National Copyright Administration issued Implementing Measures for the Copyright Administrative Penalties (Revision Draft for Comment


吉利德丙肝药sovaldi最新专利申请遭中国拒绝
  • Beijing Sanyou Intellectual Property Agency Ltd
  • China
  • September 11 2015

根据美国游说组织I-MAK消息吉利德公司的重磅级丙肝药物专利申请遭到中国SIPO拒绝这是在I-MAK提出专利授予前异议后做出的决定I-MAK还联合其他公益性组织对该药物在欧盟印度和俄罗斯等其他市场的专利申请发起挑战索非布韦核心专利此前已经在印度和埃及遭到拒绝


China’s national antitrust authority fights administrative monopoly in Provincial Government drug procurement programs
  • Sidley Austin LLP
  • China
  • September 7 2015

On August 17, 2015, one of China's antitrust enforcement authorities, the National Development & Reform Commission (NDRC), issued a letter to the


Antitrust in China's pharma sector Bengbu action following big-bang reform
  • Hogan Lovells
  • China
  • September 1 2015

On 26 August 2015, the National Development and Reform Commission ("NDRC") made public its first antitrust enforcement decision in the pharmaceutical


Experimental use exemption of patent infringement ̶ a brief comparison of China and the United States
  • Peksung Intellectual Property Ltd
  • China, USA
  • February 3 2015

Generally, the purpose of a patent is to award the patentee a limited market monopoly for disclosing his invention to the public. Experimental use of


Global intellectual property newsletter - issue 0115
  • Clifford Chance LLP
  • China, European Union, Germany, Poland, Spain, United Kingdom, USA
  • January 21 2015

Establishment of the Unified European Patent Litigation System has been subject to many efforts of European leaders and legislators for more than four